Mitoxantrone Injection,
USP
General Information: Mitoxantrone Injection USP is typically utilized in acute nonlymphocytic leukemia and advanced hormone-refractory prostate cancer. For indication, dosing or other information, please refer to the manufacture package insert.
|
| |
| Manufacturer |
Product |
Size |
NDC |
PI |
MSDS |
| Hospira |
Mitoxantrone |
2 mg/mL - 10mL |
61703-0343-18 |
PI |
MSDS |
| |
|
2 mg/mL - 12.5 mL |
61703-0343-65 |
PI |
MSDS |
| |
|
2mg/mL - 15mL |
61703-0343-66 |
PI |
MSDS |
| |
|
|
|
|
|
| TEVA |
Mitoxantrone |
2mg/mL -10mL |
00703-4685-01 |
PI |
MSDS |
| |
|
2mg/mL -12.5mL |
00703-4680-01 |
PI |
MSDS |
| |
|
2mg/mL-15mL |
00703-4686-01 |
PI |
MSDS |
|
| |
| Clinical
Data: For any questions
or for further information
related to Mitoxantrone
Injection, USP, clinical
pharmacology, additional
indications and usages,
contraindications, warnings,
precautions, adverse reactions,
dosage, administration and/or
storage of this product, please
contact
BDI Pharma or call 1-800-948-9834. |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |